Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

Clinical trial NCT04886596 · COMPLETED

Trial details

NCT number: NCT04886596
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Respiratory Syncytial Virus Infections

Start date: 2021-05-25
Primary completion: 2022-04-11
Enrollment: 26675

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.